Medlab Clinical has completed a A$15m capital raising to fund Phase 3 clinical trials in the US, UK and Australia as well as US expansion, research programs and partnering discussions around its NanoCelle delivery technology.
The placement was supported by existing and new institutional and sophisticated investors.
CEO Sean Hall said: “The support shown for the placement has been extremely pleasing and appreciated. Following completion… the company will have in excess of $16 million in cash.”
